[go: up one dir, main page]

NO20051345L - Humane anti-IFN-gamma noytraliserende antistoffer som selektive IFN-gamma reaksjonsvei inhibitorer - Google Patents

Humane anti-IFN-gamma noytraliserende antistoffer som selektive IFN-gamma reaksjonsvei inhibitorer

Info

Publication number
NO20051345L
NO20051345L NO20051345A NO20051345A NO20051345L NO 20051345 L NO20051345 L NO 20051345L NO 20051345 A NO20051345 A NO 20051345A NO 20051345 A NO20051345 A NO 20051345A NO 20051345 L NO20051345 L NO 20051345L
Authority
NO
Norway
Prior art keywords
ifn
gamma
neutralizing antibodies
human anti
pathway inhibitors
Prior art date
Application number
NO20051345A
Other languages
English (en)
Other versions
NO336802B1 (no
Inventor
Andrew A Welcher
Haichun Huang
Hilary T Chute
Yue Li
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO20051345L publication Critical patent/NO20051345L/no
Publication of NO336802B1 publication Critical patent/NO336802B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)

Abstract

Sammendrag Foreliggende oppfinnelse tilveiebringer antistoffer som interagerer med eller binder til humant interferon-gamma (IFN-() og fremgangsmåter for behandling av IFN-( medierte sykdommer ved administrering av en farmasøytisk effektiv mengde av antistoffer til IFN-(. Fremgangsmåter for å detektere mengden av IFN-( i en prøve ved anvendelse av antistoffer til IFN-( er også fremskaffet.
NO20051345A 2002-10-16 2005-03-15 Humane anti-IFN-gamma nøytraliserende antistoffer samt fremstilling derav, isolert polynukleotid, vektor, vertcelle og farmasøytisk sammensetning NO336802B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41905702P 2002-10-16 2002-10-16
US47924103P 2003-06-17 2003-06-17
PCT/US2003/032871 WO2004035747A2 (en) 2002-10-16 2003-10-16 Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors

Publications (2)

Publication Number Publication Date
NO20051345L true NO20051345L (no) 2005-05-13
NO336802B1 NO336802B1 (no) 2015-11-02

Family

ID=32110210

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051345A NO336802B1 (no) 2002-10-16 2005-03-15 Humane anti-IFN-gamma nøytraliserende antistoffer samt fremstilling derav, isolert polynukleotid, vektor, vertcelle og farmasøytisk sammensetning

Country Status (26)

Country Link
US (5) US7335743B2 (no)
EP (2) EP2298811B8 (no)
JP (2) JP4252061B2 (no)
KR (1) KR100816124B1 (no)
CN (1) CN1820026B (no)
AT (1) ATE520416T1 (no)
AU (2) AU2003285874A1 (no)
BR (1) BR0315161A (no)
CA (1) CA2501653C (no)
CY (1) CY1111812T1 (no)
DK (1) DK1578936T3 (no)
EA (1) EA011876B1 (no)
EG (1) EG26731A (no)
ES (1) ES2370473T3 (no)
IL (1) IL167436A (no)
ME (2) ME00205B (no)
MX (1) MXPA05003907A (no)
NO (1) NO336802B1 (no)
NZ (1) NZ538893A (no)
PL (1) PL377338A1 (no)
PT (1) PT1578936E (no)
RS (1) RS52690B (no)
SG (1) SG155054A1 (no)
SI (1) SI1578936T1 (no)
WO (2) WO2004034988A2 (no)
ZA (1) ZA200503821B (no)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335743B2 (en) * 2002-10-16 2008-02-26 Amgen Inc. Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
DK1848744T3 (da) 2005-01-27 2012-03-19 Novimmune Sa Humane anti-interferon-gamma-antistoffer og fremgangsmåder til anvendelse heraf
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
GB0704038D0 (en) * 2007-03-02 2007-04-11 Deepstream Technologies Ltd Nulling current transformer
US20110097318A1 (en) * 2007-08-31 2011-04-28 Amgen Inc. Solid-State Protein Formulation
EP2205280B1 (en) * 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
EP2219602A1 (en) 2007-11-15 2010-08-25 Amgen, Inc Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
WO2009134489A2 (en) * 2008-02-01 2009-11-05 Albany Medical College Blockage of interferon-gamma for prevention of polymicrobial synergy
CA2721052C (en) * 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CA2778105C (en) 2009-10-23 2019-04-02 Amgen Inc. Vial adapter and system
WO2011098518A2 (en) * 2010-02-11 2011-08-18 Ablynx Nv Delivery of immunoglobulin variable domains and constructs thereof
CA2800919C (en) 2010-06-07 2019-01-15 Amgen Inc. Drug delivery device
EP2679681B2 (en) 2011-02-25 2023-11-15 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific FC antibody
WO2012135315A1 (en) 2011-03-31 2012-10-04 Amgen Inc. Vial adapter and system
AU2012245231B2 (en) 2011-04-20 2016-10-13 Amgen Inc. Autoinjector apparatus
EA030868B1 (ru) 2011-10-14 2018-10-31 Эмджен Инк. Инжектор и способ его сборки
WO2013078378A1 (en) * 2011-11-23 2013-05-30 Amgen Inc. Methods of treatment using an antibody against interferon gamma
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EP3072548B1 (en) 2012-11-21 2019-03-06 Amgen, Inc Drug delivery device
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
EP3593839A1 (en) 2013-03-15 2020-01-15 Amgen Inc. Drug cassette
CA2897825C (en) 2013-03-22 2022-05-24 Scott R. Gibson Injector and method of assembly
RU2539752C2 (ru) * 2013-05-23 2015-01-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО И АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ (Fab), СВЯЗЫВАЮЩИЕСЯ С ИНТЕРФЕРОНОМ- γ ЧЕЛОВЕКА, ФРАГМЕНТЫ ДНК, КОДИРУЮЩИЕ УКАЗАННОЕ АНТИТЕЛО И АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ, КЛЕТКА, ТРАНСФОРМИРОВАННАЯ ФРАГМЕНТОМ ДНК, И СПОСОБ ПОЛУЧЕНИЯ УКАЗАННОГО АНТИТЕЛА И АНТИГЕНСВЯЗЫВАЮЩЕГО ФРАГМЕНТА
US10112995B2 (en) 2013-07-03 2018-10-30 Immunoqure Ag Human anti-IFN-α antibodies
WO2015035215A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
US10815296B2 (en) 2013-09-16 2020-10-27 Children's Hospital Medical Center Methods of treatment of HSCT-associated thrombotic microangiopathy with eculizumab
AU2014340174B2 (en) 2013-10-24 2019-09-12 Amgen Inc. Drug delivery system with temperature-sensitive control
US11097055B2 (en) 2013-10-24 2021-08-24 Amgen Inc. Injector and method of assembly
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
CA3193070A1 (en) 2014-05-07 2015-11-12 Amgen Inc. Autoinjector with shock reducing elements
AU2015259053B2 (en) 2014-05-16 2020-12-24 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
JP6817074B2 (ja) 2014-06-03 2021-01-20 アムジエン・インコーポレーテツド 制御可能な薬物送達システム及び使用方法
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
KR102230549B1 (ko) 2014-09-12 2021-03-22 삼성디스플레이 주식회사 접촉 감지 기능을 가진 광학계 및 이를 포함하는 표시 장치
JP6766040B2 (ja) 2014-10-14 2020-10-07 アムジエン・インコーポレーテツド 視覚および可聴インジケータを備える薬剤注射装置
JP2017538512A (ja) 2014-12-19 2017-12-28 アムジエン・インコーポレーテツド ライブボタンまたはユーザインタフェースフィールドを含む薬物送達装置
WO2016133947A1 (en) 2015-02-17 2016-08-25 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
ES2905870T3 (es) 2015-02-27 2022-04-12 Amgen Inc Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
WO2016177913A1 (en) 2015-05-07 2016-11-10 Novimmune Sa Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers
EP3307318A4 (en) 2015-06-09 2019-01-16 Children's Hospital Medical Center DOSAGE ALGORITHM FOR COMPLEMENT INHIBITOR
WO2017027861A1 (en) 2015-08-13 2017-02-16 Amgen Inc. Charged depth filtration of antigen-binding proteins
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
EP3386573B1 (en) 2015-12-09 2019-10-02 Amgen Inc. Auto-injector with signaling cap
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
US11200298B2 (en) 2016-03-15 2021-12-14 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
EP3455142B1 (en) 2016-05-13 2023-08-09 Amgen Inc. Vial sleeve assembly
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
MX2019008432A (es) 2017-01-17 2019-11-18 Amgen Inc Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje.
EP3582825A1 (en) 2017-02-17 2019-12-25 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
CA3052204A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Insertion mechanism for drug delivery device
JP2020508803A (ja) 2017-03-06 2020-03-26 アムジエン・インコーポレーテツド 作動防止特徴部を備える薬物送達デバイス
AU2018230546B2 (en) 2017-03-07 2024-03-21 Amgen Inc. Needle insertion by overpressure
CA3052310A1 (en) 2017-03-09 2018-09-13 Amgen Inc. Insertion mechanism for drug delivery device
JP7672196B2 (ja) 2017-03-14 2025-05-07 アムジエン・インコーポレーテツド 細胞培養において産生される抗体の総非フコシル化グリコフォームの調節
KR20240042212A (ko) 2017-03-28 2024-04-01 암겐 인코포레이티드 플런저 로드 및 주사기 조립 시스템 및 방법
TWI797124B (zh) 2017-05-05 2023-04-01 香港商安立璽榮生醫(香港)有限公司 抗干擾素-γ之抗體及其應用
AU2018282077B2 (en) 2017-06-08 2023-11-23 Amgen Inc. Torque driven drug delivery device
WO2018226515A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
JP7195276B2 (ja) 2017-06-22 2022-12-23 アムジエン・インコーポレーテツド デバイス起動による衝突／衝撃の低減
EP3641861A1 (en) 2017-06-23 2020-04-29 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
WO2019014014A1 (en) 2017-07-14 2019-01-17 Amgen Inc. NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM
CN107177613A (zh) * 2017-07-18 2017-09-19 哈尔滨紫霞生物科技有限公司 一种提高重组猪干扰素‑γ融合蛋白抗病毒活性的方法
IL271173B2 (en) 2017-07-21 2024-04-01 Amgen Inc Gas permeable sealing member for drug container and methods of assembly
MA49676A (fr) 2017-07-25 2020-06-03 Amgen Inc Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
EP4085942A1 (en) 2017-07-25 2022-11-09 Amgen Inc. Drug delivery device with gear module and related method of assembly
US11661447B2 (en) * 2017-08-03 2023-05-30 The Cleveland Clinic Foundation Human β2-glycoprotein I expression
WO2019032482A2 (en) 2017-08-09 2019-02-14 Amgen Inc. HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM
WO2019036181A1 (en) 2017-08-18 2019-02-21 Amgen Inc. BODY INJECTOR WITH STERILE ADHESIVE PATCH
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
EP3691717B1 (en) 2017-10-04 2023-02-08 Amgen Inc. Flow adapter for drug delivery device
EP3691716B1 (en) 2017-10-06 2023-11-29 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
EP3694578B1 (en) 2017-10-09 2025-09-24 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
EP3703779A1 (en) 2017-11-03 2020-09-09 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
US20200261648A1 (en) 2017-11-06 2020-08-20 Amgen Inc. Drug delivery device with placement and flow sensing
MA50569A (fr) 2017-11-06 2020-09-16 Amgen Inc Ensembles de remplissage-finition et procédés associés
EP3706826A1 (en) 2017-11-10 2020-09-16 Amgen Inc. Plungers for drug delivery devices
MA50903A (fr) 2017-11-16 2021-05-12 Amgen Inc Auto-injecteur avec détection de décrochage et de point d'extrémité
SG11202003004RA (en) 2017-11-16 2020-04-29 Amgen Inc Door latch mechanism for drug delivery device
EP3717004A4 (en) * 2017-12-01 2021-12-01 Children's Hospital Medical Center COMPOSITIONS FOR BLOCKING INTERERONS AND THEIR METHODS OF USE
CN108060113B (zh) * 2017-12-14 2021-03-30 福建农林大学 一株能稳定表达抗干扰素γ的基因工程单链抗体株及应用
CN108314730B (zh) * 2017-12-29 2019-01-08 珠海泰诺麦博生物技术有限公司 抗破伤风毒素中和抗体及其制备与应用
EP3775251A1 (en) 2018-03-26 2021-02-17 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
CN112105373B (zh) * 2018-03-29 2024-04-05 安立玺荣(上海)生物医药科技有限公司 治疗b型肝炎病毒感染的方法
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023451A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
US12303677B2 (en) 2018-07-24 2025-05-20 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
CA3103681A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
CA3103105A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
WO2020068623A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
IL281469B2 (en) 2018-09-28 2024-08-01 Amgen Inc Muscle wire escapement activation assembly for a drug delivery device
JP2022503983A (ja) 2018-10-02 2022-01-12 アムジエン・インコーポレーテツド 内力伝達を伴う薬物送達用の注入システム
EP3860686A1 (en) 2018-10-05 2021-08-11 Amgen Inc. Drug delivery device having dose indicator
EA202191038A1 (ru) 2018-10-15 2021-07-06 Эмджен Инк. Способ платформенной сборки для устройства доставки лекарственного средства
KR102848295B1 (ko) 2018-10-15 2025-08-20 암젠 인크 댐핑 메커니즘을 갖는 약물 전달 장치
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
MA54057A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
EP3873566B1 (en) 2018-11-01 2024-11-27 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
MX2021012557A (es) 2019-04-24 2021-11-12 Amgen Inc Conjuntos y metodos de verificacion de esterilizacion de jeringuillas.
EP4017560A2 (en) 2019-08-23 2022-06-29 Amgen, Inc Drug delivery device with configurable needle shield engagement components and related methods
CA3152547A1 (en) 2019-09-26 2021-04-01 Amgen Inc. Methods of producing antibody compositions
CN113018424B (zh) * 2019-12-25 2023-05-02 中国科学院分子细胞科学卓越创新中心 Cst1在预防和/或治疗肝脏免疫失调疾病中的应用
WO2021207150A1 (en) * 2020-04-06 2021-10-14 Celledit Llc Genetically modified immune cells expressing a chimeric antigen receptor and having reduced proinflammatory cytokine signaling
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
WO2021206766A1 (en) 2020-04-09 2021-10-14 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
EP3892280A3 (en) 2020-04-09 2022-01-12 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
JP2023548767A (ja) 2020-10-15 2023-11-21 アムジエン・インコーポレーテツド 抗体製造方法における相対不対グリカン
CN112794903B (zh) * 2021-04-14 2021-06-25 广州市雷德生物科技有限公司 一种特异性结合IFN-γ的抗体及其应用
BR112023024278A2 (pt) 2021-05-21 2024-01-30 Amgen Inc Método de otimizar uma receita de enchimento para um recipiente de fármacos
WO2022261021A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
EP4413377A1 (en) 2021-10-05 2024-08-14 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
CN114778817A (zh) * 2022-06-17 2022-07-22 山东中鸿特检生物科技有限公司 一种检测血清和血浆中干扰素的试剂盒及检测方法与应用
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
CN116284381B (zh) * 2023-05-16 2023-09-05 北京百普赛斯生物科技股份有限公司 抗IFN-γ的抗体及其应用
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025153527A1 (en) 2024-01-19 2025-07-24 Englmeier Ludwig Diagnostic use of immunoglobulin e
EP4588490A1 (en) 2024-01-19 2025-07-23 Englmeier, Ludwig Diagnostic use of immunoglobulin e
EP4663240A1 (en) 2024-06-12 2025-12-17 Ospedale San Raffaele S.r.l. Ifn- pathway inhibitors for use in the treatment of fshd
CN119591707B (zh) * 2025-02-10 2025-04-29 细胞生态海河实验室 抗人IFN-γ抗体及其应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
AU561343B2 (en) * 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5582824A (en) 1981-10-19 1996-12-10 Genentech, Inc. Recombinant DES-CYS-TYR-CYS human immune interferon
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4599306A (en) * 1983-04-15 1986-07-08 Amgen Monoclonal antibodies which specifically bind to human immune interferon
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
FR2584418B1 (fr) * 1985-07-05 1988-11-10 Unicet Laboratoires Anticorps monoclonaux contre le g-interferon, hybridomes produisant de tels anticorps, procede de preparation de tels anticorps et de tels hybridomes, leur utilisation pour differencier les gifs, et ensemble ou " kit " utilisant de tels anticorps
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
NL8700927A (nl) 1987-04-16 1988-11-16 Stichting Rega V Z W Anti-interferon-gamma-antilichamen; en hun therapeutische toepassing.
CA1335792C (en) * 1987-08-18 1995-06-06 Chaim O. Jacob Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
ATE102631T1 (de) * 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
IL88378A (en) * 1988-11-14 2000-11-21 Yeda Res & Dev Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU648505B2 (en) 1989-05-19 1994-04-28 Amgen, Inc. Metalloproteinase inhibitor
IT1231727B (it) 1989-08-11 1991-12-21 Enrico Savoldi Peptidi utili per la determinazione e la purificazione di anticorpi anti gamma interferone.
EP0497867A1 (en) * 1989-10-23 1992-08-12 Schering Corporation Polypeptide inhibitors of gamma interferon
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US20040010810A1 (en) * 1990-01-12 2004-01-15 Abgenix, Inc. Generation of xenogeneic antibodies
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5451658A (en) 1990-09-27 1995-09-19 Schering Corporation Antagonists of human gamma interferon
CA2111348A1 (en) 1991-06-14 1992-12-23 John S. Logan Production of human hemoglobin in transgenic pigs
NL9101290A (nl) 1991-07-23 1993-02-16 Stichting Rega V Z W Recombinant dna-molecuul voor de expressie van een fv-fragment van een antilichaam.
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
DE4213497A1 (de) 1992-04-24 1993-10-28 Max Delbrueck Centrum Verfahren zur Herstellung von monoklonalen Antikörpern gegen humanes Interferon-gamma
JP3887011B2 (ja) * 1992-12-29 2007-02-28 ジェネンテク，インコーポレイテッド ＩＦＮ−γインヒビターによる炎症性腸疾患の処置
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US20030059428A1 (en) * 1993-02-26 2003-03-27 Boris Skurkovich Treatment of autoimmune diseases
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
AU7015396A (en) * 1995-09-07 1997-03-27 Health Research Incorporated Cyclin e variants and use thereof
AU2452797A (en) 1996-04-10 1997-10-29 Board Of Trustees Of The University Of Illinois, The Interferon-gamma anti-inflammatory methods, compounds, and pharmaceutical compositions
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US20030228310A1 (en) * 1996-12-23 2003-12-11 Advanced Biotherapy, Inc. Treatment of skin diseases
US5852824A (en) * 1997-05-22 1998-12-22 Brown; Roger W. Apparatus and method for processing year-date data in computer systems
US6350860B1 (en) * 1997-08-18 2002-02-26 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
MXPA01005515A (es) * 1998-12-01 2003-07-14 Protein Design Labs Inc Anticuerpos humanizados para gamma-interferon.
ATE305506T1 (de) * 1998-12-09 2005-10-15 Protein Design Labs Inc Verwendung von il-12 antikörpern zur behandlung von psoriasis
US6329510B1 (en) * 1999-01-29 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-CCR1 antibodies and methods of use therefor
EP1173485A1 (en) 1999-05-03 2002-01-23 Medarex, Inc. Human antibodies to staphylococcus aureus
IL147765A0 (en) 1999-07-29 2002-08-14 Medarex Inc HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
GB0001710D0 (en) 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic treatment
US6699473B2 (en) * 2000-10-13 2004-03-02 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US7335743B2 (en) * 2002-10-16 2008-02-26 Amgen Inc. Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
WO2013180295A1 (ja) 2012-06-01 2013-12-05 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
AU2003285874A8 (en) 2004-05-04
CA2501653A1 (en) 2004-04-29
US8529893B2 (en) 2013-09-10
ES2370473T3 (es) 2011-12-16
RS52690B (sr) 2013-08-30
US20140004127A1 (en) 2014-01-02
EP2298811A3 (en) 2011-05-18
ZA200503821B (en) 2006-03-29
ATE520416T1 (de) 2011-09-15
EA011876B1 (ru) 2009-06-30
MEP30308A (en) 2010-10-10
AU2003286437B2 (en) 2008-03-13
EP1578936A2 (en) 2005-09-28
MXPA05003907A (es) 2005-06-17
WO2004034988A3 (en) 2006-07-27
EP2298811A2 (en) 2011-03-23
PL377338A1 (pl) 2006-01-23
BR0315161A (pt) 2005-08-16
EP2298811B1 (en) 2014-11-26
KR100816124B1 (ko) 2008-03-21
JP4252061B2 (ja) 2009-04-08
SG155054A1 (en) 2009-09-30
AU2003286437A1 (en) 2004-05-04
EA200500497A2 (ru) 2006-02-24
AU2003285874A1 (en) 2004-05-04
WO2004034988A2 (en) 2004-04-29
EP1578936B1 (en) 2011-08-17
HK1084689A1 (en) 2006-08-04
IL167436A (en) 2011-08-31
NO336802B1 (no) 2015-11-02
US20080107655A1 (en) 2008-05-08
US20110045537A1 (en) 2011-02-24
KR20050059213A (ko) 2005-06-17
CA2501653C (en) 2015-01-27
US20120269819A1 (en) 2012-10-25
PT1578936E (pt) 2011-09-05
US20050004353A1 (en) 2005-01-06
US8906371B2 (en) 2014-12-09
NZ538893A (en) 2008-06-30
JP2009082133A (ja) 2009-04-23
EP1578936A4 (en) 2007-03-14
WO2004035747A2 (en) 2004-04-29
EA200500497A3 (ru) 2006-08-25
CY1111812T1 (el) 2014-02-12
ME00205B (me) 2011-02-10
RS20050298A (sr) 2007-08-03
US7790859B2 (en) 2010-09-07
EP2298811B8 (en) 2015-02-18
JP2006508689A (ja) 2006-03-16
EG26731A (en) 2014-06-22
DK1578936T3 (da) 2011-12-05
WO2004035747A3 (en) 2005-11-17
US8202976B2 (en) 2012-06-19
US7335743B2 (en) 2008-02-26
SI1578936T1 (sl) 2012-02-29
CN1820026B (zh) 2010-06-23
CN1820026A (zh) 2006-08-16

Similar Documents

Publication Publication Date Title
NO20051345L (no) Humane anti-IFN-gamma noytraliserende antistoffer som selektive IFN-gamma reaksjonsvei inhibitorer
MEP31508A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
DK1534335T3 (da) FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
PL375041A1 (en) Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
CY1111263T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης
ATE485517T1 (de) Verfahren zur identifizierung von polypeptid- targets
SE0302312D0 (sv) Peptide-based passive immunization therapy for treatment of atherosclerosis
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
BRPI0515115A (pt) método de tratar uma doença de pele proliferativa
CR7618A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: AMGEN INC, US

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: AMGEN INC., US

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: AMGEN INC., US

MM1K Lapsed by not paying the annual fees